Johnson_ad.qxp 4/1/08 12:13 Page 51
Help us to hold on
as long as we can.
Reminyl helps keep them together.
Reminyl is licensed for the symptomatic treatment of mild to moderate Alzheimer’s dementia.
1
Prescribing Information. (Please refer to full Summaries of Product Characteristics [SmPCs] before prescribing). Rhinitis, urinary tract infections, anorexia, weight decrease, confusion, depression (very rarely with suicidality),
Reminyl
®
XL 8mg, 16mg and 24mg prolonged release capsules; Reminyl 4mg, 8mg and 12mg Tablets and insomnia, dizziness, somnolence, syncope, tremor, abdominal pain, diarrhoea, dyspepsia, asthenia, fatigue, fever,
4mg/ml Oral Solution. Presentation: Galantamine (as hydrobromide) provided as 8mg, 16mg and 24mg capsules; headache, malaise, fall, injury. Uncommon (>1/1,000, <1/100): Paraesthesia, tinnitus, atrial arrhythmia, myocardial
4mg, 8mg and 12mg tablets; and 4mg/ml oral solution. Uses: Symptomatic treatment of mild to moderately severe infarction, myocardial ischaemia, palpitation, cerebrovascular disease, transient ischaemic attack, leg cramps. Rare
Alzheimer’s dementia (AD). Dosage and administration: Oral. Confirm diagnosis of probable mild to moderately (>1/10,000, <1/1,000): Dehydration (leading to renal insufficiency and renal failure), hypokalaemia, aggression,
severe AD prior to treatment. Adults/Elderly: Capsules to be taken once daily (o.d.).Tablets and oral solution to be taken agitation, hallucinations, seizures, bradycardia (severe), rash. Very rare (<1/10,000): Worsening of Parkinsonism, AV
twice daily (b.d.). Ensure adequate fluid intake during treatment. Capsules to be swallowed whole not chewed or crushed. block, hypotension, dysphagia, gastrointestinal bleeding, increased sweating. Overdose: General supportive measures.
Starting dose: 8mg/day (8mg o.d. or 4mg b.d.) for 4 weeks. Initial maintenance dose: 16mg/day (16mg o.d. or 8mg b.d.) Atropine in severe cases. Basic NHS price: Capsules: 8mg x 28: £54.60; 16mg x 28: £68.32; 24mg x 28: £84.00.
for at least 4 weeks. Maintenance dose: 24mg/day (24mg o.d. or 12mg b.d.). Evaluate patients regularly - see SmPCs for Tablets: 4mg x 56: £54.60; 8mg x 56: £68.32; 12mg x 56: £84.00. Oral Solution: 4mg/ml x 100ml: £120.00. Legal
full details. Consider reducing dose to 16mg/day if patient cannot tolerate higher dose or no increased benefit shown. category: POM. Product Licence numbers: Capsules: PL 08557/0052-0054, Tablets: PL 08557/0039-0041 and
Moderate hepatic impairment: reduce dose - see SmPCs. Children: Not recommended. Contraindications: Oral Solution: PL 08557/0042. Product Licence holder: Shire Pharmaceuticals Limited, Hampshire International
Hypersensitivity, severe hepatic/severe renal impairment, patients with both significant renal and hepatic dysfunction. Business Park,Chineham, Basingstoke, Hampshire, RG24 8EP, UK. Date of revision: November 2005. Further
Special Warnings and Precautions: Benefit has not been demonstrated in other types of dementia or memory information is available from: Shire Pharmaceuticals Limited, Hampshire International Business Park, Chineham,
impairment (e.g. mild cognitive impairment) - see SmPCs. Cardiovascular conditions, predisposition or history of Basingstoke, Hampshire, RG24 8EP, UK.Tel: 01256 894000. Reminyl is a registered trademark of Shire Pharmaceutical
gastrointestinal ulcers, gastrointestinal obstruction/surgery, convulsions, cerebrovascular disease, severe asthma, Development Limited in the UK. Reference: 1. Reminyl XL Summary of Product Characteristics, July 2005.
obstructive pulmonary disease or active pulmonary infections (e.g. pneumonia), urinary obstruction, bladder surgery. Date of preparation: December 2007. UK/REM/07/098.
Capsules: contain sucrose. Tablets: contain lactose and 12mg tablet also contains E110. Oral solution: contains methyl and
propyl parahydroxybenzoate. Interactions: Other cholinomimetics, beta-blockers, digoxin, anaesthetics, CYP2D6 or
Adverse events should be reported to the Yellow Card Scheme. Information about adverse
CYP3A4 inhibitors.Also, for capsules: certain calcium-channel blocking agents, amiodarone. Pregnancy and Lactation:
event reporting via this scheme can be found at www.yellowcard. gov.uk.
Not recommended. Undesirable Effects: Very common (>1/10): Nausea, vomiting. Common (>1/100, <1/10): Adverse events may also be reported to Shire Pharmaceuticals Ltd on 01256 894000.
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68